Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1300/S. 297 PSA screening bills; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills).
2025 · 1st Quarter (Jan 1 - Mar 31)
ASTELLAS PHARMA US, INC.
Filed by ASTELLAS PHARMA US, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- Not reported
- Expenses
- $560,000.00
- Registrant
- ASTELLAS PHARMA US, INC.
- Client
- ASTELLAS PHARMA US, INC.
- Filing UUID
- 6d1b5ed4-25fa-40ad-b54d-f7438507a22f
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to menopause; Issues related to implementation of the Inflation Reduction Act (H.R. 5376).
Literal federal measure citations: H.R. 1300, S. 297, H.R. 5376
Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).
Issues related to Pharmacy Benefit Manager reform, S. 392 Give Kids a Chance Act; Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills).
Literal federal measure citations: S. 392, H.R. 1300, S. 297
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.